This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health professional risk communication

Archived - Important Safety Information Regarding the Use of Effexor® (venlafaxine HCI) Tablets and Effexor® XR (venlafaxine HCI) Capsules in Children and Adolescents - Wyeth Pharmaceuticals

Starting date:
September 24, 2003
Posting date:
September 24, 2003
Type of communication:
Dear Healthcare Professional Letter
Subcategory:
Drugs, Affects children, pregnant or breast feeding women
Source of recall:
Health Canada
Audience:
Healthcare Professionals
Identification number:
RA-17000510

This is duplicated text of a letter from Wyeth Pharmaceuticals.

Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

[Text of letter begins]

IMPORTANT SAFETY INFORMATION regarding the use of Effexor® (venlafaxine HCI) Tablets and Effexor® XR (venlafaxine HCI) Capsules in children and adolescents

September 10, 2003

Dear Health Care Professional,

Following discussions with Health Canada, Wyeth wishes to inform you about important emerging safety information on the use of Effexor® (venlafaxine HCI) Tablets and Effexor® XR (venlafaxine HCI) Capsules in children and adolescents. A Dear Health Care Professional Letter was issued in the United States on August 22, 2003. The same information is being distributed in Canada. See attached copyFootnote 1.

We are now working with Health Canada to update the Canadian labeling.

In Canada, Effexor® Tablets and Effexor® XR Capsules have not been and are not recommended for use in patients under 18 years.

If you have any questions about this information, please contact Wyeth Medical Information at

1-800-461-8844.

Sincerely,

original signed by

Neil Maresky, M.B., B. Ch.

Vice President

Scientific Affairs

Wyeth Canada has voluntarily sent a copy of the US letter to Health Canada to inform them of the safety information conveyed to Health Care Professionals in the US and indicated that a labeling change in Canada would be forthcoming.

Any suspected adverse incident can also be reported to:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)

Marketed Health Products Directorate

HEALTH CANADA

Address Locator: 0201C2

OTTAWA, Ontario, K1A 1B9

Tel: (613) 957-0337 or Fax: (613) 957-0335

Toll free for consumers and health professionals:

Tel: 866 234-2345, Fax: 866 678-6789

cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the TPD web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

References:

Footnotes

Footnote 1

Wyeth Pharmaceuticals, in the United States (US), voluntarily sent out a Dear Health Care Professional Letter on August 22, 2003 to inform Health Care Professionals about changes to the Effexor® Tablets and Effexor® XR Extended Release Capsules Prescribing Information. Attached is a copy of the US Letter for your information.

Return to footnote 1 referrer

[Text of letter ends]
Date modified: